Moderna Stock: How Far Can The Flu Shot Fly?

Moderna (MRNA) – a developer of mRNA-focused therapeutics and vaccines – has recorded a 6-day winning streak, accumulating gains of 25% during this time. The company's market capitalization has increased by approximately $4.0 billion over the past 6 days and now sits at $20 billion.

Forbes • 8 hours ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed to review a Moderna flu vaccine.

Reuters • Feb 23, 2026

Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear

Moderna helped to rapidly create vaccines for COVID-19, leading to a financial windfall. But those vaccine sales have waned, and so has the company's top line.

The Motley Fool • Feb 23, 2026

Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January.

Philippe Laffont bought shares of CoreWeave in the first quarter of last year and recently closed that position. The investor favors tech stocks and innovators.

The Motley Fool • Feb 21, 2026

BioNTech sues Moderna for patent infringement over COVID-19 shots

Biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNexspike infringes a patent related to BioNTech and Pfizer's competing shot Comirnaty.

Reuters • Feb 19, 2026

Moderna Stock Jumps After FDA Reverses Course on Flu Shot

MRNA stock rises 6% as the FDA agrees to review its flu vaccine filing after a surprise reversal, with a decision expected by Aug. 5, 2026.

Zacks Investment Research • Feb 19, 2026

Moderna to Present at Upcoming Conferences in March 2026

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, on Tuesday, March 3rd at 1:50pm ET Barclays 28th Annual Global Healthcare Conference, on Tuesday, March 10th at 9:30am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.

Accesswire • Feb 19, 2026

US FDA to initiate review of Moderna's influenza vaccine

Moderna said on Wednesday the U.S. Food and Drug Administration has accepted its application to review its influenza vaccine candidate.

Reuters • Feb 18, 2026

FDA agrees to review Moderna's mRNA flu vaccine application in a reversal

Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the shot available for the upcoming influenza season.

CNBC • Feb 18, 2026

FDA reverses decision not to review Moderna's new flu vaccine

The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.

New York Post • Feb 18, 2026